Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106600 · ClinicalTrials.gov registry record · Phase 1
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00106600: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT00106600 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106600, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an additional 86 patients will be enrolled. During this part of the study, the safety and effectiveness will be evaluated.
Interventions
- DRUG Pixantrone IV infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106600
The ClinicalTrials.gov registry entry for NCT00106600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pixantrone IV infusion is the first listed.
NCT00106600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106600 about?
NCT00106600 is a clinical study titled "Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)". The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an additional 86 patients will be enrolled. During this part of the study, the safety and effectiveness will be evalua...
What is the current status of trial NCT00106600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00106600?
The interventions under investigation include: Pixantrone IV infusion (DRUG).
Who is sponsoring clinical trial NCT00106600?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.